Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis
Authors:
Open Access
- 25 March 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (11) , 9476-9487
Abstract
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasisKeywords
This publication has 43 references indexed in Scilit:
- MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor SignalingCell, 2012
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 StudyClinical Cancer Research, 2011
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomesNature Medicine, 2011
- Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast CancerClinical Breast Cancer, 2011
- Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activationOncogene, 2011
- Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intoleranceCancer, 2010
- A chemical and phosphoproteomic characterization of dasatinib action in lung cancerNature Chemical Biology, 2010
- Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformationLaboratory Investigation, 2008
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006